Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oxford Endovascular

Request full access

Origami-inspired flow diverter for treating brain aneurysms

Oxford, United KingdomFounded 2015Health Tech & Medtech

About Oxford Endovascular

Oxford Endovascular Limited is a medical device company spun out from the University of Oxford in 2015. The company is focused on developing and commercializing a next-generation flow-diverter stent, named OXIFLOW, for the minimally invasive treatment of intracranial aneurysms, a condition affecting one in 50 people. The company's clients are primarily healthcare providers, such as hospitals and specialized neurovascular clinics. It operates within the global MedTech market for brain aneurysm devices, which is valued at nearly $3 billion annually.

The company was founded by Professor of Neuroradiology James Byrne and Professor of Engineering Zhong You, who invented the OXIFLOW device. Professor Byrne is a world-renowned physician who pioneered endovascular coiling in the UK, and his clinical experience highlighted the need for a more precise device. Professor You is a leading expert in deployable 'origami' engineering and space-age satellite technologies. This cross-disciplinary collaboration led to the creation of the OXIFLOW stent. Mike Karim, an entrepreneur with nearly 30 years of experience in the medical device industry, joined as a co-founder and serves as the CEO.

The core product, OXIFLOW, is a metallic mesh tube inspired by origami principles. It is laser-cut from Nitinol, an advanced nickel-titanium alloy known for its shape-memory properties. Delivered via a microcatheter, the device is designed to open more accurately and conform better to the patient's blood vessels compared to conventional stents. This diverts blood flow away from the aneurysm, allowing it to heal and reducing the risk of rupture and life-threatening brain hemorrhage. The design aims to mitigate complications, which can occur in up to 35% of existing aneurysm treatments, and make more patients eligible for treatment.

Oxford Endovascular's business model is centered on research, development, and the eventual commercialization of its patented device. The company has successfully raised significant capital to fund its development and move towards clinical trials. It secured a $10 million Series A round in April 2021 and a further £8 million in a Series A+ round in May 2024. Major investors include Parkwalk Advisors, Norcliffe Capital, Oxford Science Enterprises (OSE), and Vulpes Investment Management. The company has also received prestigious grants from the European Union's Horizon 2020 programme and Innovate UK.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
74.4/100
Industry
Health
Sub-industry
Medical Devices
Sector
Surgery, Neurology, Spinout, Sustainable Development Goals, European Health Catapult (EIT Health), European Health Catapult 2017 (EIT Health), Start-Up Rescue Instrument (EIT Health)
Technology
Hardware, Deep Tech, Nanotech
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing May 2025 $660K — UK Research and Innovation —
SERIES AOther financing May 2024 $11M $42M University of Oxford · Norcliffe Capital · Parkwalk Advisors · Vulpes Investment Management ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Oxford Endovascular website traffic

Latest recorded traffic for Oxford Endovascular is 90 monthly website visits, down 90.4% over the last three months. Oxford Endovascular's team declined 18.2% over the past year.

Latest monthly visits90 3-month web change-90.4% 1-year team growth-18.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oxford Endovascular in the Oxford ecosystem

Live from Dealroom

The Oxford Endovascular office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • EIT Health
  • UK Research and Innovation

Series A8 investors entered at this stage

  • Parkwalk Advisors
  • Vulpes Investment Management
  • Additio Investment Group
  • Perivoli Innovations
  • Oxford Investment Consultants
  • University of Oxford
  • Oxford Science Enterprises
  • Norcliffe Capital

Other known investors6 additional known investors

  • MedTech Innovator
  • Oxford University Innovation
  • D+V Nachfolge
  • Moti Vyas
  • OUI Startup Incubator
  • University of Bristol Enterprise Fund
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Oxford Endovascular’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.